On July 31, Renmin Pharmaceutical(600079) issued an announcement that its controlling subsidiary Wuhan Jiulong Human Well Pharmaceutical Co., Ltd. recently received the "Drug Registration Certificate" for Drospirenone Ethinyl Estradiol Tablets approved and issued by the State Food and Drug Administration.

The drug is a tablet, with each tablet containing 0.03 mg of ethinyl estradiol and 3 mg of drospirenone. It is registered as a Class 4 chemical drug, with the approval number being National Medicine Standard H20254968, and is valid until July 28, 2030.

Jiulong Human Well submitted its marketing authorization application for drospirenone and ethinyl estradiol tablets, used for female contraception, to the National Medical Products Administration in March 2024 and received acceptance. Jiulong Human Well has invested approximately 8.5 million yuan in research and development. According to MinEnet data, national sales of drospirenone and ethinyl estradiol tablets in 2024 were approximately 320 million yuan. This approval qualifies the company to sell the drug in the domestic market, further enriching its product line and expected to have a positive impact on the company.

In the first quarter of 2025, Renmin Pharmaceutical achieved revenue of 6.137 billion yuan and net profit attributable to shareholders of the parent company of 540 million yuan.

来源：https://finance.eastmoney.com/a/202507313472759426.html